ArticleResearch square2025
Illuminating the Druggable Human Proteome with an AI Protein Profiling Platform.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Creating a ligandable atlas for the proteome would transform our understanding of protein functions and accelerate therapeutic discovery; however, proteomic approaches are constrained by insufficient proteome coverage and data heterogeneity, while existing machine learning (ML) models have limited power due to structural dependencies and heterogeneous experimental labels. Here we developed AiPP, a multimodal AI platform that predicts and characterizes ligand interaction sites directly from protein sequence. AiPP is powered by the evolutionary-scale protein large language models (LLMs) and leverages two harmonized ML training sets derived from the new databases comprising cysteine ligandability from activity-based protein profiling (ABPP) studies and reversible binding evidenced from co-crystal structures. We developed a LLM representation based clustering framework to interrogate, reconcile, and augment experimental labels in both databases. Two complementary protocols were implemented to iteratively expand the training data while improving model performance. Although trained exclusively on ABPP data, AiPP recovers 80% (Top-1) of cysteine liganding events from cocrystal structures, with 84% AUPRC and 89% AUROC. AiPP recapitulates consistently and heterogeneously liganded cysteines across cancer cell lines and reliably identifies dynamic, ligandable pockets in "undruggable" transcription factors. Remarkably, AiPP accurately predicts active-site and allosteric cysteines in protein tyrosine phosphatases that were undetected by ABPP. Finally, we applied AiPP to the entire human proteome, identifying ligandable sites in proteins that were undetected or unliganded by ABPP, including an allosteric site in MC3R, which is a therapeutic target for treatment of eating disorder and obesity. This proteomewide covalent ligandability atlas (version 1.0) is anticipated to guide future development of chemical probes and pharmaceutical modulators, particularly for understudied proteins and currently undruggable targets. The LLM-based approach to interrogate large-scale heterogeneous data is broadly applicable to protein research and development of proteomics-derived ML models for diverse applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.